Bio-Rad Laboratories (BIO) – Research Analysts’ Weekly Ratings Changes

Bio-Rad Laboratories (NYSE: BIO) has recently received a number of price target changes and ratings updates:

• 5/15/2026 – Bio-Rad Laboratories is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $320.00 price target on the stock.
• 5/14/2026 – Bio-Rad Laboratories was upgraded by Royal Bank Of Canada to “moderate buy”.
• 5/6/2026 – Bio-Rad Laboratories was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 5/1/2026 – Bio-Rad Laboratories had its price target lowered by Wells Fargo & Company from $320.00 to $290.00. They now have an “equal weight” rating on the stock.
• 4/7/2026 – Bio-Rad Laboratories was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $300.00 price target on the stock, down from $375.00.

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.